Related Experiment Video

Updated: Aug 18, 2026

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
11:03

A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model

Published on: October 30, 2019

[Glucocorticoid therapy in collagen diseases diseases]

L Unger1, M Kayser, M Enderlein

  • 1I. Medizinische Klinik, Städtisches Klinikum Dresden-Friedrichstadt, Friedrichstrasse 41, 01067 Dresden, Germany. unger-le@khdf.de

Zeitschrift Fur Rheumatologie
|May 4, 2005
PubMed

Insights

Glucocorticoids are essential for treating connective tissue diseases due to their potent anti-inflammatory effects. While vital, especially in severe cases, future treatments aim to minimize side effects with newer options.

Area of Science:

  • Rheumatology and Immunology
  • Pharmacology

Context:

  • Connective tissue diseases (CTDs) necessitate potent anti-inflammatory and immunomodulatory treatments.
  • Glucocorticoids are currently indispensable for managing CTD activity and organ manifestations.

Purpose:

  • To review the critical role of glucocorticoids in managing connective tissue diseases.
  • To discuss current treatment strategies, including high-dose and intravenous pulse therapy.
  • To explore future directions in corticosteroid therapy and steroid-sparing agents.

Summary:

  • Glucocorticoids are vital for CTD treatment, with dosage tailored to disease activity and organ involvement.
  • High-dose or intravenous pulse glucocorticoid therapy is crucial in life-threatening situations.
  • Even with other immunosuppressants, glucocorticoids remain mandatory for long-term CTD management.
  • In specific patient groups (elderly, renal/hepatic impairment), glucocorticoids offer a favorable risk-benefit profile.
  • Emerging therapies, including new corticosteroids and biologics, aim to reduce glucocorticoid-induced side effects.

Impact:

  • Optimized glucocorticoid use balances disease control with minimized complications.
  • Future therapeutic regimens will integrate disease management with prophylaxis of comorbidities like osteoporosis and infections.
  • Advancements promise improved long-term outcomes for patients with connective tissue diseases.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Connective Tissue Cell Types01:22

Connective Tissue Cell Types

Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...